BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 16085232)

  • 1. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
    Grenader T; Peretz T; Lifchitz M; Shavit L
    Breast; 2005 Aug; 14(4):264-8. PubMed ID: 16085232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
    Narod SA; Risch H; Moslehi R; Dørum A; Neuhausen S; Olsson H; Provencher D; Radice P; Evans G; Bishop S; Brunet JS; Ponder BA
    N Engl J Med; 1998 Aug; 339(7):424-8. PubMed ID: 9700175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.
    Iodice S; Barile M; Rotmensz N; Feroce I; Bonanni B; Radice P; Bernard L; Maisonneuve P; Gandini S
    Eur J Cancer; 2010 Aug; 46(12):2275-84. PubMed ID: 20537530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
    Foretova L; Machackova E; Navratilova M; Pavlu H; Hruba M; Lukesova M; Valik D
    Hum Mutat; 2004 Apr; 23(4):397-8. PubMed ID: 15024741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Sun P; Tulman A; Narod SA; Lubinski J
    Breast Cancer Res Treat; 2006 Jan; 95(2):105-9. PubMed ID: 16261399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
    Olivier RI; van Beurden M
    Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
    [No Abstract]   [Full Text] [Related]  

  • 10. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
    Swisher E
    Curr Womens Health Rep; 2003 Feb; 3(1):27-32. PubMed ID: 12521547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
    Ursin G; Henderson BE; Haile RW; Pike MC; Zhou N; Diep A; Bernstein L
    Cancer Res; 1997 Sep; 57(17):3678-81. PubMed ID: 9288771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
    Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendations for the management of women with an increased genetic risk of gynaecological cancer].
    Verheijen RH; Boonstra H; Menko FH; de Graaff J; Vasen HF; Kenter GG
    Ned Tijdschr Geneeskd; 2002 Dec; 146(50):2414-8. PubMed ID: 12518519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
    Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
    Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.